English  |  正體中文  |  简体中文  |  總筆數 :2856408  
造訪人次 :  53368368    線上人數 :  849
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"epstein r j"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 1-9 / 9 (共1頁)
1 
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2022-06-10T06:11:12Z Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; ZHONG-ZHE LIN; Chao T.-Y.; Cheng A.-L.
臺大學術典藏 2021-09-01T01:54:16Z Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; ANN-LII CHENG
臺大學術典藏 2021-08-11T03:46:49Z Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; ZHONG-ZHE LIN; Chao T.-Y.; Cheng A.-L.
臺大學術典藏 2021-07-03T03:34:46Z Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; PEI-JER CHEN; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L.
臺大學術典藏 2020-04-28T07:25:28Z Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Chih-Hung Hsu;Yang T.-S.;Hsu C.;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; CHIH-HUNG HSU; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L.
臺大學術典藏 2020-04-28T07:25:28Z Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Chih-Hung Hsu;Yang T.-S.;Hsu C.;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; CHIH-HUNG HSU; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:51:20Z Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Hsu C.-H.;Yang T.-S.;Chiun Hsu;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; Hsu C.-H.; Yang T.-S.; Chiun Hsu; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:51:20Z Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Hsu C.-H.;Yang T.-S.;Chiun Hsu;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; Hsu C.-H.; Yang T.-S.; Chiun Hsu; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L.
臺大學術典藏 2010 Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Hsu C.-H.; Yang T.-S.; CHIUN HSU; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L.

顯示項目 1-9 / 9 (共1頁)
1 
每頁顯示[10|25|50]項目